Zobrazeno 1 - 10
of 200
pro vyhledávání: '"M, Vandenbranden"'
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 297(3)
The formation of R- and S-norfluoxetine was analyzed in vitro in human liver microsomes. Low apparent K(m) values for R-norfluoxetine formation ofor =8 microM and S-norfluoxetine of0.2 microM were determined. R-Norfluoxetine formation rates in a char
Publikováno v:
The Journal of biological chemistry. 275(38)
Cationic liposomes are used as vectors for gene delivery both in vitro and in vivo. Comprehension of both DNA/liposome interactions on a molecular level and a description of structural modifications involved, are prerequisites to an optimization of t
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 28(5)
The UDP-glucuronosyltransferases (UGTs) are a superfamily of membrane-bound enzymes whose active site is localized inside the endoplasmic reticulum. Glucuronidation using human liver microsomes has traditionally involved disruption of the membrane ba
Autor:
S, Ekins, G, Bravi, B J, Ring, T A, Gillespie, J S, Gillespie, M, Vandenbranden, S A, Wrighton, J H, Wikel
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 288(1)
To begin to build an understanding of the interactions of CYP2B6 with substrates, two different 3-dimensional quantitative structure activity relationship (3D-QSAR) models were constructed using 16 substrates of B-lymphoblastoid expressed CYP2B6. A p
Autor:
S, Ekins, M, Vandenbranden, B J, Ring, J S, Gillespie, T J, Yang, H V, Gelboin, S A, Wrighton
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 286(3)
Previous studies in this laboratory have determined the lack of specificity of several antibody and substrate probes of CYP2B6. The goals of the current study were to examine the expression of CYP2B6 in a bank of human liver microsome (HLM) samples u
Autor:
W J, Ehlhardt, J M, Woodland, T M, Baughman, M, Vandenbranden, S A, Wrighton, J S, Kroin, B H, Norman, S R, Maple
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 26(1)
Compound LY335979 is a P-glycoprotein inhibitor currently entering phase I clinical trials for potential reversal of multidrug resistance to cancer chemotherapy. In early exploratory studies, LY335979 was found to be rapidly transformed in incubation
Autor:
B D, Haehner, J C, Gorski, M, Vandenbranden, S A, Wrighton, S K, Janardan, P B, Watkins, S D, Hall
Publikováno v:
Molecular pharmacology. 50(1)
It has been proposed that excessive intrarenal conversion of cortisol to 6 beta-hydroxycortisol by CYP3A may mediate increased tubular reabsorption of sodium, leading to a state of mild volume expansion and the clinical phenotype of salt-sensitive hy
Publikováno v:
Clinical Nutrition. 22:S101-S102
Autor:
S D, Hall, M A, Hamman, A E, Rettie, L C, Wienkers, W F, Trager, M, Vandenbranden, S A, Wrighton
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 22(6)
Publikováno v:
Archives of biochemistry and biophysics. 306(1)
In an effort to identify and characterize minor forms of human liver cytochrome P450, immunoblot analyses of microsome samples were developed with antibodies to various P450s that recognized multiple human P450s. Four P450s were recognized in immunob